Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

138.64USD
9:00pm BST
Change (% chg)

$-1.83 (-1.30%)
Prev Close
$140.47
Open
$140.53
Day's High
$140.90
Day's Low
$138.40
Volume
2,306,458
Avg. Vol
1,937,424
52-wk High
$148.32
52-wk Low
$118.62

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $357,562.41
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.52

Financials

  JNJ.N Industry Sector
P/E (TTM): 22.53 30.93 32.76
EPS (TTM): 5.91 -- --
ROI: 13.49 15.07 14.61
ROE: 22.63 16.59 16.33

Exclusive: India, U.S. closing in on package deal to remove trade irritants

NEW DELHI Indian farmers and U.S. manufacturers of medical devices could be among the main winners in a trade package under negotiation, as Washington and New Delhi look to remove long-standing irritants to ties, sources familiar with the talks said.

18 Sep 2018

J&J to work with India on compensation for recalled hip implants

MUMBAI Johnson & Johnson (J&J) said it would work with the Indian government to compensate patients who had suffered from hip implants that were recalled by the U.S. healthcare firm eight years ago after data showed high failure rates.

07 Sep 2018

J&J to work with India on compensation for recalled hip implants

MUMBAI Johnson & Johnson (J&J) said it would work with the Indian government to compensate patients who had suffered from hip implants that were recalled by the U.S. healthcare firm eight years ago after data showed high failure rates.

07 Sep 2018

Bayer, J&J's bid to further widen use of Xarelto hits snag

FRANKFURT Bayer and Johnson & Johnson's campaign to widen the patient group for their heart drug Xarelto hit a snag when two smaller studies failed to show a statistically reliant benefit.

27 Aug 2018

Bayer, J&J's bid to further widen use of Xarelto hits snag

FRANKFURT, Aug 27 Bayer and Johnson & Johnson's campaign to widen the patient group for their heart drug Xarelto hit a snag when two smaller studies failed to show a statistically reliant benefit.

27 Aug 2018

Bayer, J&J's heart drug Xarelto fails trial to widen use

FRANKFURT Bayer and Johnson & Johnson's campaign to widen the market for its heart drug Xarelto hit a snag on Sunday when a study for a potential new patient subgroup failed to show a statistically reliant benefit.

26 Aug 2018

Bayer, J&J's heart drug Xarelto fails trial to widen use

FRANKFURT, Aug 26 Bayer and Johnson & Johnson's campaign to widen the market for its heart drug Xarelto hit a snag on Sunday when a study for a potential new patient subgroup failed to show a statistically reliant benefit.

26 Aug 2018

Oklahoma Medicaid tests new tactic to curb U.S. drug costs

LOS ANGELES A new front in the battle over the cost of expensive medicines in the United States is opening up in Oklahoma, the first state where the government's Medicaid program is negotiating contracts for prescription drugs based on how well they work.

23 Aug 2018

Oklahoma Medicaid tests new tactic to curb U.S. drug costs

LOS ANGELES, Aug 23 A new front in the battle over the cost of expensive medicines in the United States is opening up in Oklahoma, the first state where the government's Medicaid program is negotiating contracts for prescription drugs based on how well they work.

23 Aug 2018

Missouri judge affirms $4.69 billion talc verdict, J&J vows to appeal

A Missouri trial court judge has affirmed the massive $4.69 billion verdict against Johnson & Johnson in a case involving 22 women and their families who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer.

22 Aug 2018

Earnings vs. Estimates